- Home
- YMAB vs URGN Comparison
YMAB vs URGN Comparison
Compare YMAB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- URGN
- Stock Information
- Founded
- YMAB 2015
- URGN 2004
- Country
- YMAB United States
- URGN United States
- Employees
- YMAB N/A
- URGN N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- URGN Health Care
- Exchange
- YMAB Nasdaq
- URGN Nasdaq
- Market Cap
- YMAB 482.4M
- URGN 547.1M
- IPO Year
- YMAB 2018
- URGN 2017
- Fundamental
- Price
- YMAB $9.35
- URGN $11.16
- Analyst Decision
- YMAB Strong Buy
- URGN Strong Buy
- Analyst Count
- YMAB 10
- URGN 5
- Target Price
- YMAB $21.00
- URGN $44.50
- AVG Volume (30 Days)
- YMAB 243.1K
- URGN 351.4K
- Earning Date
- YMAB 11-08-2024
- URGN 11-06-2024
- Dividend Yield
- YMAB N/A
- URGN N/A
- EPS Growth
- YMAB N/A
- URGN N/A
- EPS
- YMAB N/A
- URGN N/A
- Revenue
- YMAB $84,553,000.00
- URGN $89,363,000.00
- Revenue This Year
- YMAB $6.46
- URGN $13.39
- Revenue Next Year
- YMAB $20.68
- URGN $45.06
- P/E Ratio
- YMAB N/A
- URGN N/A
- Revenue Growth
- YMAB N/A
- URGN 15.64
- 52 Week Low
- YMAB $6.09
- URGN $10.60
- 52 Week High
- YMAB $20.90
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- YMAB 32.17
- URGN 36.66
- Support Level
- YMAB $9.31
- URGN $11.08
- Resistance Level
- YMAB $11.10
- URGN $11.67
- Average True Range (ATR)
- YMAB 0.72
- URGN 0.51
- MACD
- YMAB -0.00
- URGN -0.10
- Stochastic Oscillator
- YMAB 3.87
- URGN 7.50
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.